Last updated: 2026-09-05 22:08:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Genelux Corporation (GNLX) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $2.44, with a market capitalization of $115.38M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $2.29 to $8.54. This page covers its latest market performance, valuation, price trends and company information.
$115.38M | |
$2.58 | |
$40.98 | |
$1.60 | |
$2.52 | |
197.27K | |
-- | |
-- | |
$8.54 | |
$2.29 | |
-- | |
-- |
Genelux Corporation (GNLX) last closed at $2.52 as of 2026-09-04 23:55:00, unchanged from the previous close of $2.52.
During the latest regular trading session, GNLX traded between $1.60 and $40.98, with a volume of 197.27K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Genelux Corporation (GNLX) moved from $2.67 to $2.44, representing a decline of 8.58% ($0.23).
The stock traded between $2.43 and $2.58 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 357.26 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 2.4%
GNLX is currently trading at $2.44, placing it 2.4% of the way from its 52-week low of $2.29 to its 52-week high of $8.54. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Genelux Corp is a late-stage biopharmaceutical firm focused on developing oncolytic viral immunotherapies for cancer. Its pipeline includes clinical and preclinical candidates designed to target tumor cells and stimulate an immune response against tumor-specific antigens. The company is focused on the development of next-generation oncolytic viral immunotherapies that are designed to generate a personalized multi-prong attack to overwhelm a tumor's sophisticated defense mechanisms.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 26 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Genelux Corporation (GNLX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.